Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 28;4(1):e000225. doi: 10.1136/lupus-2017-000225

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Association between serum osteopontin (OPN) and damage accrual. (A) Correlation between serum levels of OPN and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Correlation coefficient and p value are not adjusted for sex, age, corticosteroids and disease duration. (B) Patients with extensive damage (ie, SDI≥3) displayed increased levels of OPN (mean 68.4 ng/mL) compared with patients with moderate damage (ie, SDI 1–2; mean 36.0 ng/mL) and no damage (ie, SDI=0; mean 35.6 ng/mL). (C) Patients with highly elevated SDI (ie, SDI increase 3–8; mean 62.9 ng/mL) and moderately elevated SDI (ie, SDI increase 1–2; mean 50.4 ng/mL) had significantly higher OPN levels compared with patients with no SDI increase (mean 34.8 ng/mL). Crosses indicate the percentage of deceased patients for each SDI category.